Screener
ClearPoint Neuro CLPT Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by ClearPoint Neuro in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: ClearPoint Neuro’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221890
| Line item | March 31, 2026 / (Unaudited) | December 31, 2025 |
|---|---|---|
| Total liabilities | 74,575 | 69,727 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value; 25,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.01 par value; 90,000,000 shares authorized at March 31, 2026 and December 31, 2025; 29,986,639 and 29,368,760 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 300 | 294 |
| Additional paid-in capital | 239,468 | 238,995 |
| Shares to be issued | 5,535 | 5,641 |
| Accumulated deficit | (226,462) | (216,910) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is ClearPoint Neuro's preferred stock, shares authorized?
- ClearPoint Neuro (CLPT) reported preferred stock, shares authorized of $25M in Q1 2026.
- How has ClearPoint Neuro's preferred stock, shares authorized changed year-over-year?
- ClearPoint Neuro's preferred stock, shares authorized decreased by 0.0% year-over-year, from $25M to $25M.
- What is the long-term trend for ClearPoint Neuro's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), ClearPoint Neuro's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $25M to $25M.
Ask your AI about ClearPoint Neuro's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude